Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
SK Bioscience logs record high sales
Annual sales reach 929 billion won; operating profits record 474 billion won
By Kan Hyeong-wooPublished : Feb. 7, 2022 - 17:14
SK Bioscience saw record sales of 929 billion won ($774 million) and operating profits of 474 billion won from last year, on the back of strong businesses in its contract manufacturing of the AstraZeneca and Novavax COVID-19 vaccines, the company said Monday.
Compared to 2020 yearly figures, SK Bioscience’s annual sales and operating profits went up by 311 percent and 1,158 percent, respectively.
About half of the annual numbers came in the fourth quarter alone as the company logged 451 billion won in sales and 254 billion won in operating profits during the period.
The biopharmaceutical firm said it will look to continue to build on the growing momentum as it plans to complete the development of its coronavirus vaccine candidate GBP510, secure more vaccine platforms and expand infrastructures this year.
SK Bioscience’s GBP510 is currently undergoing the third and last phase of clinical trials.
Compared to 2020 yearly figures, SK Bioscience’s annual sales and operating profits went up by 311 percent and 1,158 percent, respectively.
About half of the annual numbers came in the fourth quarter alone as the company logged 451 billion won in sales and 254 billion won in operating profits during the period.
The biopharmaceutical firm said it will look to continue to build on the growing momentum as it plans to complete the development of its coronavirus vaccine candidate GBP510, secure more vaccine platforms and expand infrastructures this year.
SK Bioscience’s GBP510 is currently undergoing the third and last phase of clinical trials.
